Ligand Pharmaceuticals Incorporated Company Profile (NASDAQ:LGND)

About Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

Ligand Pharmaceuticals Incorporated logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:LGND
  • CUSIP: 53220K50
  • Web:
  • Market Cap: $3.03 billion
  • Outstanding Shares: 21,053,000
Average Prices:
  • 50 Day Moving Avg: $137.91
  • 200 Day Moving Avg: $122.00
  • 52 Week Range: $87.50 - $144.86
  • Trailing P/E Ratio: 351.05
  • Foreward P/E Ratio: 37.29
  • P/E Growth: 1.53
Sales & Book Value:
  • Annual Revenue: $117.07 million
  • Price / Sales: 25.88
  • Book Value: $19.45 per share
  • Price / Book: 7.40
  • EBITDA: $60.55 million
  • Net Margins: 7.39%
  • Return on Equity: 5.05%
  • Return on Assets: 2.94%
  • Debt-to-Equity Ratio: 0.06%
  • Current Ratio: 0.87%
  • Quick Ratio: 0.84%
  • Average Volume: 240,257 shs.
  • Beta: 1.01
  • Short Ratio: 28.6

Frequently Asked Questions for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)

What is Ligand Pharmaceuticals Incorporated's stock symbol?

Ligand Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals Incorporated's earnings last quarter?

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) issued its quarterly earnings data on Monday, August, 7th. The company reported $0.67 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.42. The business had revenue of $28 million for the quarter, compared to analysts' expectations of $24.40 million. Ligand Pharmaceuticals Incorporated had a net margin of 7.39% and a return on equity of 5.05%. The company's revenue was up 43.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.50 earnings per share. View Ligand Pharmaceuticals Incorporated's Earnings History.

When will Ligand Pharmaceuticals Incorporated make its next earnings announcement?

Ligand Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Ligand Pharmaceuticals Incorporated.

What guidance has Ligand Pharmaceuticals Incorporated issued on next quarter's earnings?

Ligand Pharmaceuticals Incorporated updated its FY17 earnings guidance on Wednesday, October, 4th. The company provided earnings per share guidance of approx $2.93 for the period, compared to the Thomson Reuters consensus estimate of $2.95. The company issued revenue guidance of atleast $134 million, compared to the consensus revenue estimate of $134.23 million.

Where is Ligand Pharmaceuticals Incorporated's stock going? Where will Ligand Pharmaceuticals Incorporated's stock price be in 2017?

4 equities research analysts have issued 12 month price objectives for Ligand Pharmaceuticals Incorporated's shares. Their forecasts range from $104.00 to $158.00. On average, they expect Ligand Pharmaceuticals Incorporated's stock price to reach $139.00 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals Incorporated.

What are analysts saying about Ligand Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals Incorporated stock:

  • 1. According to Zacks Investment Research, "Ligand’s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Moreover, with regard to Ligand's internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Nonetheless, Ligand’s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is also encouraging. Shares of Ligand have outperformed the broader industry this year so far. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to either of these two products could have a substantial impact. Estimates have remained stable ahead of the Q3 earnings. The company has a mixed record of earnings surprises in the recent quarters." (10/12/2017)
  • 2. HC Wainwright analysts commented, "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business model.Ligand seeks out value-based acquisitions of companies and technologies that have led to both current and anticipated revenue streams, Pantginis commented in his initiation note. This has also resulted in the company's reputation of reporting sustained profitability.Ligand is also an early pioneer of contingent value rights for its acquisitions, the analyst continued. As such, earnings growth is supported by the company's increasing royalty streams that are also a "significant spreading out of risk" (9/5/2017)

Who are some of Ligand Pharmaceuticals Incorporated's key competitors?

Who are Ligand Pharmaceuticals Incorporated's key executives?

Ligand Pharmaceuticals Incorporated's management team includes the folowing people:

  • Matthew W. Foehr, President, Chief Operating Officer
  • John L. Higgins, Chief Executive Officer, Director
  • Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance
  • Charles S. Berkman J.D., Vice President, General Counsel, Secretary
  • John W. Kozarich, Non-Executive Independent Chairman of the Board
  • Nancy Ryan Gray, Director
  • Jason M. Aryeh, Independent Director
  • Todd C. Davis, Independent Director
  • John L. LaMattina Ph.D., Independent Director

Who owns Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Fisher Asset Management LLC (0.27%), Eqis Capital Management Inc. (0.04%) and Round Table Services LLC (0.01%). Company insiders that own Ligand Pharmaceuticals Incorporated stock include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals Incorporated.

Who sold Ligand Pharmaceuticals Incorporated stock? Who is selling Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC and Eqis Capital Management Inc.. Company insiders that have sold Ligand Pharmaceuticals Incorporated stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

Who bought Ligand Pharmaceuticals Incorporated stock? Who is buying Ligand Pharmaceuticals Incorporated stock?

Ligand Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Round Table Services LLC. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.

How do I buy Ligand Pharmaceuticals Incorporated stock?

Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals Incorporated's stock price today?

One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $143.93.

MarketBeat Community Rating for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  158 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $139.00 (3.43% downside)
Consensus Price Target History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Price Target History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Analysts' Ratings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017HC WainwrightSet Price TargetBuy$157.00N/AView Rating Details
10/11/2017Roth CapitalReiterated RatingBuy$135.00 -> $158.00N/AView Rating Details
8/9/2017StephensReiterated RatingOverweight$125.00 -> $137.00LowView Rating Details
8/8/2017Deutsche Bank AGBoost Price TargetHold$103.00 -> $104.00HighView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
10/5/2016Craig HallumBoost Price Target$150.00 -> $160.00N/AView Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Earnings by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Earnings History by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017$0.25$0.67$24.40 million$28.00 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
2017 EPS Consensus Estimate: $2.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.43$0.43$0.43
Q2 20171$0.60$0.60$0.60
Q3 20171$0.75$0.75$0.75
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)


Dividend History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Institutional Ownership by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/5/2017John L HigginsCEOSell5,000$130.00$650,000.00View SEC Filing  
8/23/2017Jason AryehDirectorSell2,000$127.99$255,980.00View SEC Filing  
8/9/2017Charles S BerkmanVPSell18,625$126.96$2,364,630.00View SEC Filing  
8/9/2017Matthew W FoehrInsiderSell6,100$127.51$777,811.00View SEC Filing  
8/8/2017John L HigginsCEOSell5,483$125.00$685,375.00View SEC Filing  
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.72View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.20View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.81View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.00View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.49View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.40View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Latest Headlines for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Loading headlines, please wait.



Ligand Pharmaceuticals Incorporated (LGND) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.